Cns Labs Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 04-07-2024
- Paid Up Capital ₹ 1.00 M
as on 04-07-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.25 Cr
as on 04-07-2024
- Revenue 71.59%
(FY 2023)
- Profit -7.48%
(FY 2023)
- Ebitda 25.38%
(FY 2023)
- Net Worth 54.53%
(FY 2023)
- Total Assets 54.59%
(FY 2023)
About Cns Labs
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.25 Cr.
Gudelli Patak, Lavanya Pothireddy, Yadamakanti Reddy, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100TG2012PTC083810
- Company No.
083810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Oct 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cns Labs Private Limited offer?
Cns Labs Private Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research, Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Cns Labs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gudelli Patak  | Director | 02-Jul-2015 | Current |
| Lavanya Pothireddy | Director | 23-Oct-2012 | Current |
| Yadamakanti Reddy | Director | 17-Jun-2023 | Current |
| Rajendra Surasani | Director | 20-Jul-2020 | Current |
Financial Performance of Cns Labs.
Cns Labs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 71.59% increase. The company also saw a slight decrease in profitability, with a 7.48% decrease in profit. The company's net worth Soared by an impressive increase of 54.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cns Labs?
In 2023, Cns Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Bell Pharmaceuticals And Cosmetics Private LimitedActive 3 years 2 months
Yadamakanti Reddy is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Dec 2022 | ₹2.25 Cr | Open |
How Many Employees Work at Cns Labs?
Cns Labs has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cns Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cns Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
